These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36020)

  • 41. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
    Willis GL
    Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Chase TN
    Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The recent advance of treatment of Parkinson's disease].
    Matsubara E
    Nihon Rinsho; 2004 Sep; 62(9):1725-8. PubMed ID: 15462392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease: new approaches to diagnosis and treatment.
    Yahr MD
    Acta Neurol Scand Suppl; 1993; 146():22-5. PubMed ID: 8333251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of motor symptoms in Parkinson's disease].
    Morís-De la Tassa G; Arias-Rodríguez M
    Rev Neurol; 2009 Jan; 48 Suppl 1():S27-31. PubMed ID: 19222012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous dopaminergic stimulation: clinical aspects and experimental bases.
    Rodriguez-Oroz MC; Marin C; de Fabregues O
    Neurologist; 2011 Nov; 17(6 Suppl 1):S30-7. PubMed ID: 22045323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pathogenesis and basis of the therapy of Parkinson's disease].
    van der Drift JH; Stoof JC
    Ned Tijdschr Geneeskd; 1981 Apr; 125(16):620-5. PubMed ID: 6113554
    [No Abstract]   [Full Text] [Related]  

  • 50. Biochemical aspects of experimentally induced parkinsonism.
    Goldstein M; Anagnoste B; Battista AF; Nakatani S; Ogawa M
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():434-47. PubMed ID: 4403657
    [No Abstract]   [Full Text] [Related]  

  • 51. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitors of dopamine inactivating systems as antiparkinson drugs.
    Youdim MB
    Adv Neurol; 1990; 53():483-8. PubMed ID: 2239488
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacotherapy of Parkinson's disease: research from 1960 to 1991.
    Pletscher A; DaPrada M
    Acta Neurol Scand Suppl; 1993; 146():26-31. PubMed ID: 8101413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
    Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 56. [Non-dopaminergic treatments for Parkinson's disease].
    Derkinderen P
    Rev Neurol (Paris); 2010 Oct; 166(10):811-5. PubMed ID: 20832090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.
    Broderick PA; Wenning L; Li YS
    J Neural Transm (Vienna); 2017 Jan; 124(1):57-78. PubMed ID: 27796511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
    Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
    Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in dopamine receptor agonists for the treatment of Parkinson's disease.
    Stocchi F; Torti M; Fossati C
    Expert Opin Pharmacother; 2016 Oct; 17(14):1889-902. PubMed ID: 27561098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The history of dopamine and levodopa in the treatment of Parkinson's disease.
    Fahn S
    Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.